Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
9Customers
1Debt Items
0Related Chains
Source-Backed Evidence Depth
NextCure, Inc. (NXTC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
2Distinct source URLs
5High confidence
0.725Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
NextCure, Inc. Suppliers
Ticker
Name
Confidence
Evidence
SIMCERE-ZAIMING-PHARMACEUTICAL-CO-LTD
SIMCERE-ZAIMING-PHARMACEUTICAL-CO-LTD
92%
Pursuant to the License Agreement, the Company obtained (1) an exclusive, worldwide (excluding the Zaiming Territory, as identified below) license to develop, manufacture, and commercialize Zaiming’s…
LIGACHEM
LIGACHEM
90%
Under the terms of the LigaChem Agreement, both parties equally share the costs of developing the ADC products and profits on commercialized products
NextCure, Inc. Customers
Ticker
Name
Confidence
Evidence
LIGACHEM-BIOSCIENCES-INC
LIGACHEM-BIOSCIENCES-INC
85%
dates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication; ● the identification, analysis and use of biomarkers and biomarker data; ●…
CO-LLC
CO-LLC
62%
s, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clini…
HAINAN-SIMCERE-ZAIMING-PHARMACEUTICAL-CO-LTD
HAINAN-SIMCERE-ZAIMING-PHARMACEUTICAL-CO-LTD
62%
ctive participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activities. A collaborative arrangement within the scope of ASC 808 may …
HAINAN-SIMCERE-ZAIMING-PHARMACEUTICAL-LTD
HAINAN-SIMCERE-ZAIMING-PHARMACEUTICAL-LTD
62%
s, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clini…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
s, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clini…
LEGOCHEM-BIOSCIENCES-INC
LEGOCHEM-BIOSCIENCES-INC
62%
dates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication; ● the identification, analysis and use of biomarkers and biomarker data; ●…
SIMCERE-ZAIMING-INC
SIMCERE-ZAIMING-INC
62%
s, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clini…
SIMCERE-ZAIMING-PHARMACEUTICAL-CO-LTD
SIMCERE-ZAIMING-PHARMACEUTICAL-CO-LTD
62%
ctive participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activities. A collaborative arrangement within the scope of ASC 808 may …
U-S-FOREIGN-CO
U-S-FOREIGN-CO
62%
our product candidates. Additionally, in February 2025, HHS ended a longstanding commitment to voluntarily comply with notice and comment requirements for public benefits rules, even when not require…
NextCure, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NXTC-DEBT
Debt stack $2.6M
90%
Market cache reports total debt of $2.6M.
NextCure, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for NextCure, Inc..
NextCure, Inc. Ownership
Holder
Name
Confidence
Evidence
NXTC-OWNER-SQUADRON-CAPITAL-MANAGEMENT-LLC
Squadron Capital Management LLC
90%
13F overlay lists Squadron Capital Management LLC as top holder; 26 tracked holders.
NextCure, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
